Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

mTORC1 activity is essential for erythropoiesis and B cell lineage commitment.

Malik N, Dunn KM, Cassels J, Hay J, Estell C, Sansom OJ, Michie AM.

Sci Rep. 2019 Nov 15;9(1):16917. doi: 10.1038/s41598-019-53141-1.

PMID:
31729420
2.

Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer.

Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, Mrowinska A, Loveridge CJ, Rushworth LK, Edwards J, Ntala C, Nixon C, Hedley A, Mackay G, Tardito S, Sansom OJ, Leung HY.

Cancer Res. 2019 Nov 12. pii: canres.1684.2019. doi: 10.1158/0008-5472.CAN-19-1684. [Epub ahead of print]

PMID:
31719098
3.

A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer.

Schmidt S, Gay D, Uthe FW, Denk S, Paauwe M, Matthes N, Diefenbacher ME, Bryson S, Warrander FC, Erhard F, Ade CP, Baluapuri A, Walz S, Jackstadt R, Ford C, Vlachogiannis G, Valeri N, Otto C, Schülein-Völk C, Maurus K, Schmitz W, Knight JRP, Wolf E, Strathdee D, Schulze A, Germer CT, Rosenwald A, Sansom OJ, Eilers M, Wiegering A.

Nat Cell Biol. 2019 Nov;21(11):1413-1424. doi: 10.1038/s41556-019-0408-0. Epub 2019 Nov 4.

PMID:
31685988
4.

Targeting the metabolic response to statin-mediated oxidative stress produces a synergistic anti-tumor response.

McGregor GH, Campbell AD, Fey SK, Tumanov S, Sumpton D, Rodriguez Blanco G, Mackay G, Nixon C, Vazquez A, Sansom OJ, Kamphorst JJ.

Cancer Res. 2019 Sep 27. pii: canres.0644.2019. doi: 10.1158/0008-5472.CAN-19-0644. [Epub ahead of print]

PMID:
31562248
5.

Correction: Lkb1 Deficiency Alters Goblet and Paneth Cell Differentiation in the Small Intestine.

Shorning BY, Zabkiewicz J, McCarthy A, Pearson HB, Winton DJ, Sansom OJ, Ashworth A, Clarke AR.

PLoS One. 2019 Sep 19;14(9):e0223041. doi: 10.1371/journal.pone.0223041. eCollection 2019.

6.

Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.

Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, Wouters VM, Roper J, Kendall TJ, Roxburgh CS, Horgan PG, Nixon C, Nourse C, Gunzer M, Clark W, Hedley A, Yilmaz OH, Rashid M, Bailey P, Biankin AV, Campbell AD, Adams DJ, Barry ST, Steele CW, Medema JP, Sansom OJ.

Cancer Cell. 2019 Sep 16;36(3):319-336.e7. doi: 10.1016/j.ccell.2019.08.003.

7.

Pancreatic Cancer: From Genome Discovery to PRECISION-Panc.

Dreyer SB, Jamieson NB, Morton JP, Sansom OJ, Biankin AV, Chang DK.

Clin Oncol (R Coll Radiol). 2019 Sep 12. pii: S0936-6555(19)30343-7. doi: 10.1016/j.clon.2019.08.007. [Epub ahead of print] No abstract available.

PMID:
31522943
8.

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.

Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI), Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P.

Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6.

9.

The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.

Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF.

J Pathol. 2019 Nov;249(3):332-342. doi: 10.1002/path.5320. Epub 2019 Jul 30.

PMID:
31259422
10.

Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis.

Rohwer N, Jumpertz S, Erdem M, Egners A, Warzecha KT, Fragoulis A, Kühl AA, Kramann R, Neuss S, Rudolph I, Endermann T, Zasada C, Apostolova I, Gerling M, Kempa S, Hughes R, Lewis CE, Brenner W, Malinowski MB, Stockmann M, Schomburg L, Faller W, Sansom OJ, Tacke F, Morkel M, Cramer T.

Oncogene. 2019 Jul;38(28):5670-5685. doi: 10.1038/s41388-019-0816-4. Epub 2019 May 1.

11.

Author Correction: Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.

Gay DM, Ridgway RA, Müller M, Hodder MC, Hedley A, Clark W, Leach JD, Jackstadt R, Nixon C, Huels DJ, Campbell AD, Bird TG, Sansom OJ.

Nat Commun. 2019 Mar 26;10(1):1453. doi: 10.1038/s41467-019-09465-7.

12.

Brf1 loss and not overexpression disrupts tissues homeostasis in the intestine, liver and pancreas.

Liko D, Mitchell L, Campbell KJ, Ridgway RA, Jones C, Dudek K, King A, Bryson S, Stevenson D, Blyth K, Strathdee D, Morton JP, Bird TG, Knight JRP, Willis AE, Sansom OJ.

Cell Death Differ. 2019 Dec;26(12):2535-2550. doi: 10.1038/s41418-019-0316-7. Epub 2019 Mar 11.

PMID:
30858608
13.

RAL GTPases Drive Intestinal Stem Cell Function and Regeneration through Internalization of WNT Signalosomes.

Johansson J, Naszai M, Hodder MC, Pickering KA, Miller BW, Ridgway RA, Yu Y, Peschard P, Brachmann S, Campbell AD, Cordero JB, Sansom OJ.

Cell Stem Cell. 2019 Apr 4;24(4):592-607.e7. doi: 10.1016/j.stem.2019.02.002. Epub 2019 Mar 7.

14.

Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.

Gay DM, Ridgway RA, Müller M, Hodder MC, Hedley A, Clark W, Leach JD, Jackstadt R, Nixon C, Huels DJ, Campbell AD, Bird TG, Sansom OJ.

Nat Commun. 2019 Feb 13;10(1):723. doi: 10.1038/s41467-019-08586-3. Erratum in: Nat Commun. 2019 Mar 26;10(1):1453.

15.

Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling.

Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, Juin A, Ismail S, Bryant DM, Markert EK, Machesky LM, Mazzone M, Sansom OJ, Zanivan S.

Sci Signal. 2019 Feb 5;12(567). pii: eaan8247. doi: 10.1126/scisignal.aan8247.

16.

AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.

Cosimo E, Tarafdar A, Moles MW, Holroyd AK, Malik N, Catherwood MA, Hay J, Dunn KM, Macdonald AM, Guichard SM, O'Rourke D, Leach MT, Sansom OJ, Cosulich SC, McCaig AM, Michie AM.

Clin Cancer Res. 2019 Mar 1;25(5):1574-1587. doi: 10.1158/1078-0432.CCR-18-2036. Epub 2018 Dec 17.

17.

Correction for Muncan et al., "Rapid Loss of Intestinal Crypts upon Conditional Deletion of the Wnt/Tcf-4 Target Gene c-Myc".

Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, Sancho E, Cole AM, Gregorieff A, Moreno de Alboran I, Clevers H, Clarke AR.

Mol Cell Biol. 2018 Nov 28;38(24). pii: e00482-18. doi: 10.1128/MCB.00482-18. Print 2018 Dec 15. No abstract available.

18.

Mannose impairs tumour growth and enhances chemotherapy.

Gonzalez PS, O'Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, Roseweir A, Gay DM, Mackay G, Malviya G, Kania E, Ritchie S, Baudot AD, Zunino B, Mrowinska A, Nixon C, Ennis D, Hoyle A, Millan D, McNeish IA, Sansom OJ, Edwards J, Ryan KM.

Nature. 2018 Nov;563(7733):719-723. doi: 10.1038/s41586-018-0729-3. Epub 2018 Nov 21.

19.

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

Spender LC, Ferguson GJ, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, Inman GJ.

Mol Pharmacol. 2019 Feb;95(2):222-234. doi: 10.1124/mol.118.112946. Epub 2018 Nov 20.

PMID:
30459156
20.

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC.

Cancer Res. 2019 Jan 1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717. Epub 2018 Nov 2.

PMID:
30389701
21.

Microenvironmental cues in cancer stemness.

Flanagan DJ, Hodder MC, Sansom OJ.

Nat Cell Biol. 2018 Oct;20(10):1102-1104. doi: 10.1038/s41556-018-0210-4. No abstract available.

PMID:
30258126
22.

The role of mTOR-mediated signals during haemopoiesis and lineage commitment.

Malik N, Sansom OJ, Michie AM.

Biochem Soc Trans. 2018 Oct 19;46(5):1313-1324. doi: 10.1042/BST20180141. Epub 2018 Aug 28. Review.

23.

Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis.

Greenhough A, Bagley C, Heesom KJ, Gurevich DB, Gay D, Bond M, Collard TJ, Paraskeva C, Martin P, Sansom OJ, Malik K, Williams AC.

EMBO Mol Med. 2018 Nov;10(11). pii: e8699. doi: 10.15252/emmm.201708699.

24.

TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence.

Bird TG, Müller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadamillas E, Lu WY, Jamieson T, Govaere O, Campbell AD, Ferreira-Gonzalez S, Cole AM, Hay T, Simpson KJ, Clark W, Hedley A, Clarke M, Gentaz P, Nixon C, Bryce S, Kiourtis C, Sprangers J, Nibbs RJB, Van Rooijen N, Bartholin L, McGreal SR, Apte U, Barry ST, Iredale JP, Clarke AR, Serrano M, Roskams TA, Sansom OJ, Forbes SJ.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaan1230. doi: 10.1126/scitranslmed.aan1230.

25.

Systems level expression correlation of Ras GTPase regulators.

Besray Unal E, Kiel C, Benisty H, Campbell A, Pickering K, Blüthgen N, Sansom OJ, Serrano L.

Cell Commun Signal. 2018 Aug 15;16(1):46. doi: 10.1186/s12964-018-0256-8.

26.

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M.

Oncogene. 2018 Dec;37(49):6368-6382. doi: 10.1038/s41388-018-0390-1. Epub 2018 Jul 30.

PMID:
30061636
27.

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.

Foth M, Ismail NFB, Kung JSC, Tomlinson D, Knowles MA, Eriksson P, Sjödahl G, Salmond JM, Sansom OJ, Iwata T.

J Pathol. 2018 Nov;246(3):331-343. doi: 10.1002/path.5143. Epub 2018 Sep 19.

28.

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP, Timpson P.

Cell Rep. 2018 Jun 12;23(11):3312-3326. doi: 10.1016/j.celrep.2018.05.038.

29.

Intestinal Stem Cell Dynamics: A Story of Mice and Humans.

Hodder MC, Flanagan DJ, Sansom OJ.

Cell Stem Cell. 2018 Jun 1;22(6):785-787. doi: 10.1016/j.stem.2018.05.005.

30.

MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.

Godfrey JD, Morton JP, Wilczynska A, Sansom OJ, Bushell MD.

Cell Death Dis. 2018 May 29;9(6):644. doi: 10.1038/s41419-018-0628-4.

31.

STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin cap.

Woroniuk A, Porter A, White G, Newman DT, Diamantopoulou Z, Waring T, Rooney C, Strathdee D, Marston DJ, Hahn KM, Sansom OJ, Zech T, Malliri A.

Nat Commun. 2018 May 29;9(1):2124. doi: 10.1038/s41467-018-04404-4.

32.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

33.

Loss of N-WASP drives early progression in an Apc model of intestinal tumourigenesis.

Morris HT, Fort L, Spence HJ, Patel R, Vincent DF, Park JH, Snapper SB, Carey FA, Sansom OJ, Machesky LM.

J Pathol. 2018 Jul;245(3):337-348. doi: 10.1002/path.5086. Epub 2018 May 28.

34.

Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation.

May S, Owen H, Phesse TJ, Greenow KR, Jones GR, Blackwood A, Cook PC, Towers C, Gallimore AM, Williams GT, Stürzl M, Britzen-Laurent N, Sansom OJ, MacDonald AS, Bird AP, Clarke AR, Parry L.

J Pathol. 2018 Jul;245(3):270-282. doi: 10.1002/path.5074. Epub 2018 May 16.

35.

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.

Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA.

Cancer Discov. 2018 Jun;8(6):764-779. doi: 10.1158/2159-8290.CD-17-0867. Epub 2018 Mar 26.

36.

Wnt ligands influence tumour initiation by controlling the number of intestinal stem cells.

Huels DJ, Bruens L, Hodder MC, Cammareri P, Campbell AD, Ridgway RA, Gay DM, Solar-Abboud M, Faller WJ, Nixon C, Zeiger LB, McLaughlin ME, Morrissey E, Winton DJ, Snippert HJ, van Rheenen J, Sansom OJ.

Nat Commun. 2018 Mar 19;9(1):1132. doi: 10.1038/s41467-018-03426-2.

37.

Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.

Patel R, Fleming J, Mui E, Loveridge C, Repiscak P, Blomme A, Harle V, Salji M, Ahmad I, Teo K, Hamdy FC, Hedley A, van den Broek N, Mackay G, Edwards J, Sansom OJ, Leung HY.

EMBO Mol Med. 2018 Apr;10(4). pii: e8347. doi: 10.15252/emmm.201708347.

38.

Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress.

Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, Hedley A, Kalna G, Lilla S, Neilson L, Brucoli M, Gyuraszova K, Tait-Mulder J, Mezna M, Svambaryte S, Bryson A, Sumpton D, McVie A, Nixon C, Drysdale M, Esumi H, Murray GI, Sansom OJ, Zanivan SR, Murphy DJ.

Cancer Discov. 2018 May;8(5):632-647. doi: 10.1158/2159-8290.CD-17-0533. Epub 2018 Mar 2.

39.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

40.

Spatiotemporal regulation of liver development by the Wnt/β-catenin pathway.

Burke ZD, Reed KR, Yeh SW, Meniel V, Sansom OJ, Clarke AR, Tosh D.

Sci Rep. 2018 Feb 9;8(1):2735. doi: 10.1038/s41598-018-20888-y.

41.

Role of Wnt signalling in advanced prostate cancer.

Ahmad I, Sansom OJ.

J Pathol. 2018 May;245(1):3-5. doi: 10.1002/path.5029. Epub 2018 Mar 1.

PMID:
29314004
42.

Accepting from the best donor; analysis of long-lifetime donor fluorescent protein pairings to optimise dynamic FLIM-based FRET experiments.

Martin KJ, McGhee EJ, Schwarz JP, Drysdale M, Brachmann SM, Stucke V, Sansom OJ, Anderson KI.

PLoS One. 2018 Jan 2;13(1):e0183585. doi: 10.1371/journal.pone.0183585. eCollection 2018.

43.

Neutrophils: Homing in on the myeloid mechanisms of metastasis.

Leach J, Morton JP, Sansom OJ.

Mol Immunol. 2019 Jun;110:69-76. doi: 10.1016/j.molimm.2017.12.013. Review.

44.

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.

Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, Egbukichi N, Amery TS, Thoma MC, Jenny ZP, Rhim AD, Murphy DJ, Sansom OJ, Crawford HC, Sheppard BC, Sears RC.

Nat Commun. 2017 Nov 23;8(1):1728. doi: 10.1038/s41467-017-01967-6.

45.

Calcium signalling links MYC to NUAK1.

Monteverde T, Tait-Mulder J, Hedley A, Knight JR, Sansom OJ, Murphy DJ.

Oncogene. 2018 Feb 22;37(8):982-992. doi: 10.1038/onc.2017.394. Epub 2017 Nov 6.

46.

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.

Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ; Australian Pancreatic Cancer Genome Initiative (APGI), Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M.

Gut. 2018 Dec;67(12):2142-2155. doi: 10.1136/gutjnl-2017-315144. Epub 2017 Oct 28.

47.

Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models.

Phesse TJ, Durban VM, Sansom OJ.

Carcinogenesis. 2017 Oct 1;38(10):953-965. doi: 10.1093/carcin/bgx080. Review.

48.

A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts.

Nobis M, Herrmann D, Warren SC, Kadir S, Leung W, Killen M, Magenau A, Stevenson D, Lucas MC, Reischmann N, Vennin C, Conway JRW, Boulghourjian A, Zaratzian A, Law AM, Gallego-Ortega D, Ormandy CJ, Walters SN, Grey ST, Bailey J, Chtanova T, Quinn JMW, Baldock PA, Croucher PI, Schwarz JP, Mrowinska A, Zhang L, Herzog H, Masedunskas A, Hardeman EC, Gunning PW, Del Monte-Nieto G, Harvey RP, Samuel MS, Pajic M, McGhee EJ, Johnsson AE, Sansom OJ, Welch HCE, Morton JP, Strathdee D, Anderson KI, Timpson P.

Cell Rep. 2017 Oct 3;21(1):274-288. doi: 10.1016/j.celrep.2017.09.022.

49.

Corrigendum: Modulating the therapeutic response of tumours to dietary serine and glycine starvation.

Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F, Blagih J, Vincent DF, Campbell KJ, Ceteci F, Sansom OJ, Blyth K, Vousden KH.

Nature. 2017 Aug 2;548(7665):122. doi: 10.1038/nature23471.

PMID:
28770843
50.

Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer.

D'Costa Z, Jones K, Azad A, van Stiphout R, Lim SY, Gomes AL, Kinchesh P, Smart SC, Gillies McKenna W, Buffa FM, Sansom OJ, Muschel RJ, O'Neill E, Fokas E.

Cancer Res. 2017 Nov 1;77(21):5952-5962. doi: 10.1158/0008-5472.CAN-16-2833. Epub 2017 Aug 1.

Supplemental Content

Loading ...
Support Center